0000874015-18-000124.txt : 20181101 0000874015-18-000124.hdr.sgml : 20181101 20181101193432 ACCESSION NUMBER: 0000874015-18-000124 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181101 FILED AS OF DATE: 20181101 DATE AS OF CHANGE: 20181101 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BENNETT C FRANK CENTRAL INDEX KEY: 0001073387 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 181155238 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-11-01 0000874015 IONIS PHARMACEUTICALS INC IONS 0001073387 BENNETT C FRANK C/O IONIS PHARMACEUTICALS, INC. 2855 GAZELLE COURT CARLSBAD CA 92010 0 1 0 0 SVP, Antisense Research Common Stock 2018-11-01 2018-11-01 4 M 0 12500 14.69 A 31896 D Common Stock 2018-11-01 2018-11-01 4 S 0 12500 49.5396 D 19396 D Employee Stock Option (right to buy) 14.69 2018-11-01 2018-11-01 4 M 0 12500 0 A 2017-01-02 2020-01-29 Common Stock 12500 9013 D Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.35 to $49.75, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. /s/Patrick R. O'Neil, attorney-in-fact 2018-11-01